MindMed to Participate in September Investor Conferences
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain healt...
2 days ago - Business Wire
MindMed readying Phase III trials for LSD therapy to treat anxiety
MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through us...
23 days ago - Market Watch
Pacific Defense Announces US Army CMFF Program Team
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMO...
Other symbols: MRNS
24 days ago - Business Wire
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat ...
24 days ago - Business Wire
FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates
The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.
24 days ago - Barrons
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stre...
Other symbols: ATAICMPSCYBN
24 days ago - Market Watch
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat b...
27 days ago - Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat b...
4 weeks ago - Business Wire
MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat b...
4 weeks ago - Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat b...
4 weeks ago - Business Wire
MindMed Appoints Stephanie fa*gan as Chief Corporate Affairs Officer
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat b...
5 weeks ago - Business Wire
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat m...
7 weeks ago - Business Wire
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat ...
2 months ago - Business Wire
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat b...
2 months ago - Business Wire
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat b...
2 months ago - Business Wire
MindMed to Participate in June Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat b...
3 months ago - Business Wire
MindMed to Participate at May Investor Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat b...
4 months ago - Business Wire
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
ATLANTA--(BUSINESS WIRE)---- $MNMD--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candi...
4 months ago - Business Wire
MindMed Reports First Quarter 2024 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat ...
4 months ago - Business Wire
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat b...
4 months ago - Business Wire
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat b...
4 months ago - Business Wire
MindMed to Present at Upcoming May Medical Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat ...
4 months ago - Business Wire
MindMed to Present at Upcoming April Medical Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...
5 months ago - Business Wire
MindMed Announces Voluntary Delisting from Cboe Canada
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...
5 months ago - Business Wire
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...
6 months ago - Business Wire
